CM
AXSM icon

Capula Management’s Axsome Therapeutics AXSM Stock Holding History

Capula Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7,720
Closed -$555K – 513
2023
Q2 		$555K Buy
+7,720
New +$570K 0.01% 266

Other funds holding AXSM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capula Management's AXSM Position: Q3 2023 in Review

Capula Management sold out of Axsome Therapeutics (AXSM) in Q3 2023, closing a stake of 7,720 shares — an estimated $555K sold.

Capula Management first reported a position in AXSM in Q2 2023 and held it in 1 quarter. The position peaked at $555K in Q2 2023. 226 funds tracked by Wall St. Rank hold AXSM as of Q3 2023.

  • Capula Management reported no remaining Axsome Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Capula Management sold 7,720 Axsome Therapeutics shares in Q3 2023, an estimated $555K.
  • Capula Management first reported a position in Axsome Therapeutics in Q2 2023 and held it in 1 quarter.
  • Capula Management's Axsome Therapeutics position peaked at $555K in Q2 2023.
  • 226 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2023.

Based on Capula Management's 13F filing for Q3 2023, filed 3 Nov 2023.